Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies
Vivos Therapeutics (NASDAQ:VVOS) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds
Vivos Therapeutics, Inc. (VVOS) Discusses Strategic Business Model Pivot and Transition in Sleep Apnea Treatment Approach Transcript [Seeking Alpha]